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Abstract
The role of endoscopic ultrasound (EUS) in evaluating 
pancreatic pathology has been well documented from 
the beginning of its clinical use. High spatial resolution 
and the close proximity to the evaluated organs within 
the mediastinum and abdominal cavity allow detection 
of small focal lesions and precise tissue acquisition 
from suspected lesions within the reach of this meth-
od. Fine needle aspiration (FNA) is considered of ad-
ditional value to EUS and is performed to obtain tissue 
diagnosis. Tissue acquisition from suspected lesions 
for cytological or histological analysis allows, not only 
the differentiation between malignant and non-ma-
lignant lesions, but, in most cases, also the accurate 
distinction between the various types of malignant le-
sions. It is well documented that the best results are 
achieved only if an adequate sample is obtained for 
further analysis, if the material is processed in an ap-
propriate way, and if adequate ancillary methods are 
performed. This is a multi-step process and could be 
quite a challenge in some cases. In this article, we 
discuss the technical aspects of tissue acquisition by 
EUS-guided-FNA (EUS-FNA), as well as the role of an 
on-site cytopathologist, various means of specimen 
processing, and the selection of the appropriate ancil-
lary method for providing an accurate tissue diagnosis 
and maximizing the yield of this method. The main 
goal of this review is to alert endosonographers, not 
only to the different possibilities of tissue acquisition, 
namely EUS-FNA, but also to bring to their attention 
the importance of proper sample processing in the 
evaluation of various lesions in the gastrointestinal 
tract and other accessible organs. All aspects of tissue 
acquisition (needles, suction, use of stylet, complica-
tions, etc .) have been well discussed lately. Adequate 
tissue samples enable comprehensive diagnoses, 
which answer the main clinical questions, thus en-
abling targeted therapy.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: All aspects of endoscopic ultrasound tissue 
acquisition have been well discussed in recent stud-
ies. In addition to discussions about important factors 
that impact tissue acquisition, in this article we have 
highlighted the methods of ancillary testing needed 
to satisfy the growing demands of precision medicine 
standards. Adequate tissue samples and appropriate 
ancillary testing enable comprehensive diagnosis, and 
answer the main clinical questions, thus enabling tar-
geted therapy.
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INTRODUCTION
Endoscopic ultrasound guided fine needle aspiration 
(EUS-FNA) is an effective and widespread method 
for the procurement of  pancreatic tissue and, as such, 
is capable of  providing an accurate preoperative diag-
nosis. EUS-FNA is also the method of  choice for the 
evaluation of  mural lesions of  the gastrointestinal tract 
and deep seated structures, such as mediastinal lesions, 
lymph nodes, liver, spleen and suprarenal glands. It has 
become very important to accurately determine the type 
of  tumor, to precisely differentiate between primary 
tumors and metastases, and to identify potentially ac-
tionable genetic mutations in order to tailor an adequate 
therapeutic approach. The novel treatment protocols 
and application of  chemotherapeutic agents are often 
based on the molecular markers present in the tumor tis-
sue, where classic cytological or histological analyses fail 
to provide necessary information for further treatment 
decisions, especially important for neo-adjuvant chemo-
therapy. Therefore, there is a growing demand to obtain 
sufficient amounts of  tissue samples from suspected 
lesions for further analyses, or for the procurement of  
core tissue for histological analysis, if  necessary.
TECHNICAL ASPECTS OF EUS-GUIDED 
TISSUE ACQUISITION
Needles
Several types of  needles for EUS-FNA are present on 
the market, and there is an abundance of  recently pub-
lished high quality references addressing this important 
issue. EUS-FNA can be performed using 25-gauge (G), 
22-G or 19-G needles. Similar diagnostic yields are re-
ported for all types of  needles[1-6]. The most widely used 
needle for EUS-FNA is the 22-G needle. Thinner and 
more flexible, the 25-G needle should have better per-
formance for targeting the uncinate process and for the 
transduodenal approach to the pancreatic head. Still, no 
significant difference in the diagnostic accuracy has been 
described[6-8]. The flexibility of  the needle is especially 
important in locations where the scope needs to be bent 
to target the lesion. However, only one study of  24 pa-
tients documented a better technical success rate of  the 
25-G needle but the study evaluated only lesions located 
in the uncinate process[3].
On the other hand, a randomized controlled study 
of  131 patients did not show a significant difference 
between the 22-G and the 25-G needle in the diagnostic 
yield, the ease of  targeting the lesion, malfunction of  the 
needle, and the complication rate[2]. A larger 19-G needle 
was developed to obtain larger amounts of  material 
from the lesions, but compared to the 22-G needle, the 
19-G needle is stiffer and has a higher rate of  technical 
failure. This is seen in particular in pancreatic head le-
sions[3]. There is one study showing that the 19-G needle 
has a higher diagnostic accuracy than the 22-G needle, 
but technical failures were excluded from the calcula-
tions[3]. In a multicenter study with the novel 19-G flex-
ible needle made of  nitinol (Expect 19 G Flex, Boston 
Scientific, Natick, MA, United States), there was no 
significant difference in diagnostic accuracy between the 
22-G and the 19-G needle, but histological core tissue 
was obtained in a larger number of  patients using the 
19-G flexible needle[9]. A needle especially designed to 
obtain core tissue for histological analysis was the Trucut 
(Cook Endoscopy, Winston Salem, NC, United States) 
biopsy needle. The idea about the needle was good, 
but the needles had weak performance due to technical 
design problems[10-12]. The ProCore (ProCore, Cook En-
doscopy) needle overcame some obvious limitations of  
the Trucut needle, enabling easier acquisition of  the core 
tissue for histological analysis due to the special design. 
However, transduodenal passage still remained a chal-
lenge[13-15]. In the ProCore gamma, there are also 22-G 
and the 25-G needles with the same design available. 
Two groups of  authors recently studied the utility of  the 
standard 19-G needle[16] and the 19-G flexible needle[17] 
for obtaining core tissue for histological analysis. The 
standard 19-G needle experienced problems with the 
transduodenal approach, while the 19-G flexible needle 
had no technical difficulties in the acquisition of  the 
specimens for histological analysis[17].
Stylet
The role of  stylets should be to prevent sample contami-
nation by cells that do not originate from the targeted 
lesion. However, three different studies have not found 
any advantage or disadvantage of  using stylets for EUS-
FNA[18-20]. The procedures in which a stylet is used may 
be clumsy and time-consuming. Although some authors 
advocate no stylet FNAs, we find it very useful for con-
tamination prevention in routine practice. Furthermore, 
the stylet can be very useful for pushing out the sample 
from the needle to the slides or into the liquid transport 
medium.
Suction
Suction applied during EUS-FNA will result in acquisi-
tion of  more material for further analysis, but it will also 
make the specimen bloodier[21,22], thus potentially hinder-
ing the morphological tissue analysis. EUS-FNA without 
suction provides specimens with less blood. Applying 
suction during EUS-FNA of  solid lesions was associ-
ated with a significantly higher sensitivity (86% vs 67%; 
P = 0.005) in one study only[21]. Another study reported 
establishing diagnoses in over 90% of  patients without 
applying suction[22]. For lymph node sampling, applying 
suction can result in significantly bloodier samples which 
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can affect the diagnostic yield of  EUS-FNA[23].
Tissue acquisition
Obtaining “diagnostic” tissue by EUS-FNA may be 
hindered by necrosis of  the suspected lesion. Obtain-
ing the tissue from the peripheral area of  the lesion or 
from multiple areas in the “fanning” way may improve 
diagnostic yield. A sufficient number of  passes must 
be performed to provide enough material for analysis, 
and in the case of  failure, the procedure needs to be 
repeated[24]. One study described the advantages of  the 
“fanning” technique in primary tumors, although these 
advantages were not described regarding lymph node 
sampling[25].
COMPLICATION
Tissue acquisition by endoscopic ultrasound is a safe 
procedure. The reported overall complication rate ranges 
from 0.3% to 2.2%. The most worrisome complication 
of  an FNA is tumor cell seeding. However, only three 
cases of  needle tract seeding following EUS-FNA have 
been reported to date[26]. The major complications of  
EUS tissue acquisition are infections of  cystic lesions, 
bleeding and acute pancreatitis[27,28]. In order to prevent 
infection, prophylactic antibiotics must be considered 
for EUS-FNA of  cystic lesions. Intracystic bleeding is 
rarely significant. A change in echogenicity of  the cystic 
fluid indicates intracystic bleeding. The bleeding usually 
resolves spontaneously, but some medications that affect 
the process of  coagulation may pose problems. In order 
to avoid bleeding, clopidogrel must be discontinued 7 
d prior to the procedure, low molecular-weight heparin 
12-24 h prior, and unfractionated heparin 6 h prior to 
EUS-FNA. Aspirin does not have to be discontinued. It 
is recommended to discontinue warfarin 5 d prior to the 
procedure and bridge it with heparin to avoid thrombot-
ic events in high risk patients[29]. Coagulation parameters 
should be checked before the procedure.
ON-SITE CYTOPATHOLOGIST
Rapid on-site evaluation (ROSE) by attending cytopa-
thologists undoubtedly improves the diagnostic yield of  
EUS-FNA, reduces costs and decrease the number of  
repeated procedures[30]. Macroscopic specimen analysis 
is of  limited value when performed by an endosonogra-
pher, but it may be useful for the rough assessment of  
specimen adequacy. When performed by an experienced 
cytopathologist[24,31], it can save time and reduce the 
number of  passes necessary to acquire additional tissue 
after the initial ROSE. The ROSE findings and clinical 
suspicions should be considered as the starting point for 
the selection of  further ancillary methods.
ANCILLARY METHODS
Individualized medicine and various options of  targeted 
therapy in modern health care increase the demands 
for molecular and other ancillary testing on small tis-
sue specimens. Requests for minimally invasive proce-
dures for tissue acquisition are especially emphasized 
in patients with unresectable malignant diseases, and 
for patients requiring neoadjuvant chemotherapy. EUS-
FNA is an efficient, cost-effective and minimally invasive 
method for tissue acquisition with diagnostic accuracy 
comparable to excisional biopsy[32].
A number of  ancillary laboratory tests are routinely 
employed in establishing diagnostic and prognostic fac-
tors in tissue specimens from various lesions of  the gas-
trointestinal tract, pancreatic masses and other accessible 
organs. These include microbiology, immunocyto(histo)
chemistry, flow cytometry, biochemical analyses, conven-
tional cytogenetics and various molecular methods.
The correct choice of  ancillary method often depends 
on the type of  aspirated sample, the quality of  the speci-
men and the preliminary cytological diagnosis (ROSE). 
It is also institution- and resource-dependent, hence, in-
house protocols and algorithms defining sample process-
ing should be developed. The on-site cytopathologist can 
serve to liaise between the laboratory and the clinician, 
triage the samples and ensure optimal sample collection 
and processing[33]. This approach is gaining in importance 
as we witness the expanding role of  cytological samples 
in providing data for targeted therapy[34].
Except in the formalin-fixed, paraffin-embedded (FFPE) 
histological tissue, a number of  ancillary tests are also easily 
performed on the EUS-guided FNA samples[27]. Specimens 
can be processed in different ways depending on the labo-
ratory set-up and the pathologist’s preference.
Most laboratories prefer at least two direct cytologi-
cal smears for ROSE, one air-dried and one ethanol-
fixed, then rinsing of  the needle for the preparation of  
cell blocks (FFPE tissue). Another method of  cell block 
preparation is simply letting the aspirated sample clot 
on the glass and then fixing it in formalin as described 
by Bellizzi and Stelow[35]. Different practices, with more 
direct slides made on the spot are not unusual in institu-
tions where a cytopathologist is present on-site to make 
the decision regarding specimen processing. The advan-
tages and disadvantages of  cell block preparation, and its 
use, are discussed elsewhere[33,36].
Core tissue for histological diagnosis is not easily ob-
tained from the pancreas and other deep-seated sites, as 
adequate tissue sampling requires special types of  needles. 
Reported sensitivities and specificities are similar for FNA 
and core biopsy for malignant diagnoses[13]. In addition, 
formalin, as a fixative, can damage DNA for molecular 
testing. Thus, EUS-FNA remains the primary means of  
establishing a tissue diagnosis preoperatively, and it en-
sures samples for ancillary testing.
A major complaint regarding EUS-FNA is that it does 
not yield enough tissue to meet the increasing demands 
for ancillary (molecular) testing[33]. This drawback can be 
overcome by implementing ROSE, which determines the 
number of  passes necessary to ensure adequate sample 
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Table 1  Possible methods of sample processing
collection, processing and storage[37]. EUS-FNA has some 
additional advantages, including sampling of  the wider 
area of  the lesion. Aspirates also usually yield more tu-
mor and less stromal cells than core biopsy[33]. The inabil-
ity to assess tissue architecture, and to determine some 
valuable prognostic factors, such as the number of  mito-
ses or angioinvasion, remains a major disadvantage. The 
assessment of  such prognostic factors can be a problem 
with small core biopsy specimens as well.
Based on the type of  specimen, some tests are more 
likely to be employed then others. Liquid samples from 
cystic pancreatic lesions need to be evaluated macro-
scopically for viscosity, which can provide valuable in-
formation about the nature of  the cyst. The cyst fluid is 
then submitted for routine cytology, biochemical analy-
sis, microbiology if  necessary, and possibly for molecular 
analysis[38]. If  the fluid is thick, direct smears, instead of  
cytospins, can be made for cytomorphologic evaluation.
For solid lesions, immunocytochemistry (ICC) or im-
munohistochemistry (IHC) are methods of  choice for 
the diagnosis and tumor subclassification. Cell blocks 
or smears can also be submitted for molecular tests if  
needed. Lymphoid tissue and liquid specimens are highly 
suitable for the flow cytometry immunophenotyping.
There are several possible means of  processing aspi-
rated samples obtained by EUS-FNA for molecular and 
other ancillary tests (Table 1).
BIOCHEMISTRY
The most useful addition to cytology in routine pre-
operative evaluation of  pancreatic cystic lesions is the 
biochemical measurement of  enzyme levels, especially 
carcinoembryonic antigen (CEA) and amylase levels[44].
The cytological analysis of  cystic lesions is accurate in 
diagnosing cystic pancreatic neoplasms and is currently 
the only method that can accurately differentiate between 
malignant and benign cysts, as well as between various 
types of  benign cysts. The diagnostic yield of  cytology 
alone is limited because, despite a high specificity, it has 
low sensitivity for detecting malignancy due to the low 
cellularity of  cystic lesions[45]. The measurements of  CEA 
and amylase levels in the cystic fluid help differentiate 
serous from mucinous cysts[46]. Mucinous cysts are con-
sidered, at least, premalignant or low-grade non-invasive 
neoplasms, but the distinction of  mucinous cystic neo-
plasms (MCN) from non-mucinous cysts is not sufficient 
to determine the need for operative treatment, as it was a 
few years ago[47]. Cysts with a low risk of  progression are 
suitable for surveillance. The threshold value of  192 ng/
mL is usually found to be distinctive between mucinous 
and non-mucinous cysts. CEA levels have limited value in 
the subclassification of  mucinous cysts[48,49], and contrary 
to early studies[50], subsequent studies[51,52] have shown 
that CEA levels do not discriminate between malignant 
and benign mucinous cysts.
Amylase levels are usually higher in post-pancreatitis 
lesions, e.g., pseudocysts, but can be elevated in mucinous 
cystic neoplasm as well. Al- Rushdan[49] reports that the 
measurements of  amylase levels do not discriminate be-
tween the various types of  MCN and intraductal papillary 
mucinous neoplasms. Nevertheless, cytology, coupled 
with biochemical measurements of  CEA and amylase 
levels in cystic fluid, is currently the best way of  assessing 
pancreatic cysts preoperatively. The addition of  molecu-
lar studies seems promising[53,54].
IMMUNOCYTOCHEMISTRY AND 
IMMUNOHISTOCHEMISTRY
A wide application of  ICC and IHC on small tissue sam-
ples enables better characterization and subclassification 
of  tumors, which have become increasingly important 
with regard to targeted therapy for malignant diseases. 
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Sample types Ancillary methods
Direct cytological smears Cytomorphological diagnostic evaluation
ICC staining
Molecular testing (FISH)
Excellent source for isolation of good quality DNA[39,40]
Cell blocks (formalin-fixed, paraffin-embedded tissue) IHC
Various molecular tests
Tissue storage
Touch imprint slides (tumor cell rich slides made by imprinting the tumor) IHC
Molecular testing (FISH)
Fresh aspirated specimens (especially of lymph nodes) Flow cytometry - immunophenotyping
RNA based gene expression studies
DNA based studies[41]
Fresh frozen (cryopreserved) FNA specimens RNA based gene expression studies
DNA based studies[42]
FTA cards (filter paper) Effective RNA and DNA preservation
Not suitable for morphology[43]
Formalin fixed paraffin embedded core tissue Histological morphologic evaluation
IHC and molecular studies
FISH: Fluorescence in situ hybridization; FNA: Fine needle aspiration; ICC: Immunocytochemistry; IHC: Immunohistochemistry.
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The main principle of  these methods is detecting and vi-
sualizing antigens on the cell surface, cytoplasm or nucle-
us. The method is suitable for FFPE samples, including 
excisional or small core biopsies or cell blocks obtained 
during EUS-FNA. It is also routinely performed on air-
dried, previously unstained direct cytological smears, 
cytospins or liquid based cytology preparations. ICC can 
also be performed on previously stained (Papanicolaou) 
and archived cytological smears.
Presently, IHC (ICC) is routinely used for the diagno-
sis and subtyping of  various tumors, and is increasingly 
used for the evaluation of  prognostic factors[55,56].
While the diagnosis of  pancreatic ductal adenocar-
cinoma does not require IHC confirmation, other solid 
neoplasms, including lymphoma, neuroendocrine tumors 
(NET), solid pseudo-papillary neoplasms or acinic cell 
carcinoma, need IHC or ICC for the final diagnosis. 
The biological behavior of  pancreatic NETs cannot be 
predicted by morphology alone, so proliferative markers, 
such as Ki-67, have become an essential tool for grading 
pancreatic NETs, which is necessary for adequate patient 
management. Spindle cell submucosal gastric tumors are 
another example of  neoplasms which require IHC or 
ICC for definitive diagnosis and grading.
Most laboratories use direct smears for ROSE, and 
cell blocks for IHC and other ancillary methods. Ma-
jor disadvantages of  cell blocks include low cellularity, 
pooled nature of  the specimen, uneven distribution of  
tumor cells in the block, and the lack of  ROSE. Because 
of  these drawbacks, we should bear in mind that direct 
smears and cytospins are also suitable for ICC.
FLOW CYTOMETRY 
IMMUNOPHENOTYPING
Flow cytometry is a technology that simultaneously mea-
sures and then analyses multiple physical characteristics 
of  single particles, usually cells, as they flow in a fluid 
stream through a laser-beam. The measured properties 
include particle relative size, relative granularity or inter-
nal complexity, and relative fluorescence intensity.
Immunophenotyping has become a fundamental step 
in the diagnosis and subclassification of  hematologic 
malignancies, especially nodal and extra nodal lymphop-
roliferative disorders. The main advantage of  the method 
is the possibility of  detecting a specific surface or cyto-
plasmatic antigen on targeted cells by applying a complete 
panel of  antibodies to small samples. Other applications 
include DNA/RNA analysis and functional analysis (oxy-
genation, enzyme activity, phagocytosis, etc.).
EUS-FNA coupled with flow cytometry has become 
widely used in evaluating the deep-seated lesions, espe-
cially mediastinal and retroperitoneal lymph nodes[57], 
and there are several described cases of  a primary lym-
phoma of  the pancreas diagnosed by EUS- FNA and 
flow cytometry[58-60]. Flow cytometry has broadened the 
usefulness of  EUS-FNA and increased its diagnostic 
yield[55].
CONVENTIONAL CYTOGENETICS
Conventional cytogenetics for detecting structural chro-
mosomal abnormalities studying the whole karyotype is 
not routinely used on EUS-FNA samples of  pancreatic 
lesions, but is used in the diagnostic algorithms of  some 
deep-seated soft tissue lesions and hematological malig-
nancies. EUS-FNA can be a good tissue source for cell 
cultures when needed[61].
MOLECULAR METHODS
With emerging targeted therapies for various types of  
malignant diseases, there is an increased demand for 
molecular testing as part of  the routine diagnostic and 
prognostic workup, as well as for research purposes. The 
main goal is to identify any actionable genetic mutations. 
EUS-FNA is a minimally invasive, highly suitable method 
of  tissue acquisition for molecular studies. The integrity 
of  DNA and RNA available from FFPE tissue is often 
compromised because of  the methods for tissue fixation 
and storage. Although genomic studies of  large archival 
FFPE cohorts are critical for molecular studies, the best 
material for molecular studies remains fresh tissue[62]. 
With improved isolation techniques, DNA isolation is 
possible from paraffin-embedded tissue. Cytological ma-
terial obtained by EUS-FNA provides good quality DNA 
regardless of  the differences in sample preparation[63]. This 
is partly due to the use of  nucleic acid-friendly fixatives 
other than formalin[34]. FNA samples for molecular stud-
ies can be processed in different ways[33], depending on the 
type of  the sampled tissue (ROSE diagnosis), the labora-
tory resources, and the type of  test needed. The choice 
of  ancillary method should be focused on answering the 
dominant clinical questions.
Various methods of  molecular analysis are employed 
in the evaluation of  pancreatic cysts and solid masses. 
The ones most frequently used in diagnostic and prog-
nostic workups are the polymerase chain reaction (PCR) 
based techniques and fluorescence in situ hybridization 
(FISH).
PCR-based DNA studies usually evaluate the kras mu-
tational status and the loss of  heterozygosity of  several 
markers situated on different chromosomes, particularly 
in the cystic pancreatic lesions, in an attempt to increase 
the diagnostic sensitivity[64,65]. After the initial enthusi-
asm, recent studies have reported low sensitivity for the 
kras mutational analysis in cystic fluid[66]. The value of  
the kras analysis in solid pancreatic masses is not as well 
documented, as there are only a limited number of  stud-
ies addressing the issue, and they have reported variable 
results[67-69]. Salek et al[70] Studied the kras mutation, p53 
and allelic loses at 9p and 18q, and have concluded that 
they are not suitable prognostic markers for pancreatic 
cancer. Nevertheless, the meta-analysis by Fuccio et al[71] 
concluded that kras mutation analysis can be helpful in 
the diagnostic workup of  pancreatic lesions when there 
is a limited tissue sample obtained and the diagnosis is 
inconclusive. A study by Pellisé et al[72] showed increased 
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sensitivity to the detection of  lymph node micrometasta-
ses using hypermethylation analysis performed by meth-
ylation-specific PCR using EUS-FNA samples from the 
lymph nodes of  patients with various types of  gastric, 
intestinal and lung cancer.
RNA studies of  gene expressions are presently limit-
ed to research purposes, but there are several reports an-
alyzing RNA expression of  various genes for diagnostic 
expression analysis[73,74], and a report studying the preser-
vation of  the sensitive RNA molecules for future use[42]. 
FISH is a molecular method performed on the intact cell 
nuclei and has the advantage of  visualization of  the cells 
with the detected abnormality. There have been several 
attempts to use FISH in the diagnostic workup of  pan-
creatic lesions using probes for different markers (chro-
mosomal polysomy, deletions, etc.). Cohorts of  included 
patients were usually small, so a comparison of  the data 
is of  limited value. The main conclusion is, that in the 
setting of  inconclusive cytology, FISH can aid in the 
diagnosis of  pancreatic malignancy[64,75,76]. On the other 
hand, FISH is crucial for the diagnosis and prognosis 
of  some tumors with well-defined chromosomal abnor-
malities and gene rearrangements, such as lung cancers 
(including metastases), lymphomas and other tumors. 
As there are no specific molecular markers identified as 
yet for the specific diagnosis of  solid or cystic pancreatic 
masses, the research area remains wide. High-throughput 
techniques look promising in finding adequate biomark-
ers for pancreatic neoplasms. Methods using DNA mi-
croarrays, comparative genomic hybridization and DNA 
sequencing can be performed on samples obtained by 
EUS-FNA, as high quality DNA can be harvested and 
adequately processed[77].
CONCLUSION
The main issue with tissue acquisition is obtaining a large 
enough sample that will be able to provide a compre-
hensive diagnosis to satisfy the growing demands for 
individualized patient management and targeted therapy 
for the malignant disease. EUS-FNA remains a minimally 
invasive, easy to perform, and altogether more effective 
method of  sampling tissue from deep-seated lesions than 
any other available method. Numerous factors influence 
the yield of  the EUS-FNA. At present, the best results 
are achieved by collaboration between a skilled endo-
sonographer performing the EUS-FNA (tissue acquisi-
tion) and an on-site cytopathologist. The choice of  the 
needle and sampling technique should be up to the per-
forming endosonographer. The preliminary cytological 
diagnosis directs further action. The ROSE findings and 
clinical suspicions should be taken as the starting point 
for the selection of  further ancillary methods. The choice 
of  specimen processing should be in accordance with 
institutional protocols and available resources in the best 
interest of  optimal patient care.
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